Search

Displaying results 541 - 550 of 7555 in total
  1. Drug

    Salicylamide

    go.drugbank.com/drugs/DB08797
    Approved

    Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. … It has similar medicinal uses to aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSSynonyms: o-hydroxybenzamide
  2. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Vayarin is currently available only by prescription in the USA [L1502]. This drug has also been used for management of hypertriglyceridemia [L1503]. … Vayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD.

  3. Drug

    Donepezil

    go.drugbank.com/drugs/DB00843
    ApprovedInvestigational

    Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia. … [L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia.

    International brands: Nomi-NoxProducts: Nb-donepezil
  4. Drug

    Activated charcoal

    go.drugbank.com/drugs/DB09278
    ApprovedInvestigational

    It works by binding to the poison in the gastric contents in a reversible fashion thus may be adminstered together with a cathartic to reduce the small intestine transit time. … It is used as a gastric decontaminant and emergency medication to treat poisonings following excessive oral ingestion of certain medications or poisons by absorbing most drugs and toxins.

    Mixtures: NO-GAS GIULIANI CARBOSYLANE, NO-GAS GIULIANI CARBOSYLANE
  5. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication. … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses.

    Synonyms: -GLUTAMYL-L-TYROSYL-L-PROLYL-(2S)-2-CYCLOHEXYLGLYCYL-N6-(3, -HYDROXY-, 15-ETHER WITH N-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-
  6. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases. … [A263306] It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of _Acinetobacter baumannii-calcoaceticus_

  7. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy. … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in

  8. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    [L13347] Capmatinib was approved by Health Canada on June 8, 2022.[L42015] … [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same

  9. Drug

    Amivantamab

    go.drugbank.com/drugs/DB16695
    ApprovedInvestigational

    [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy

  10. Drug

    Atorvastatin

    go.drugbank.com/drugs/DB01076
    ApprovedInvestigational

    [A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. … [T568] It is a pentasubstituted pyrrole [A177415] formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound.

    Products: Nb-atorvastatin